IRIS Accounts Production v25.4.0.155 SC520422 Board of Directors 1.12.24 30.11.25 30.11.25 0 0 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh SC520422 2024-11-30 SC520422 2025-11-30 SC520422 2024-12-01 2025-11-30 SC520422 2023-11-30 SC520422 2023-12-01 2024-11-30 SC520422 2024-11-30 SC520422 ns14:PoundSterling 2024-12-01 2025-11-30 SC520422 ns10:Director1 2024-12-01 2025-11-30 SC520422 ns10:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 SC520422 ns10:SmallEntities 2024-12-01 2025-11-30 SC520422 ns10:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 SC520422 ns10:SmallCompaniesRegimeForDirectorsReport 2024-12-01 2025-11-30 SC520422 ns10:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 SC520422 ns10:FullAccounts 2024-12-01 2025-11-30 SC520422 ns5:CurrentFinancialInstruments 2025-11-30 SC520422 ns5:CurrentFinancialInstruments 2024-11-30 SC520422 ns5:ShareCapital 2025-11-30 SC520422 ns5:ShareCapital 2024-11-30 SC520422 ns5:RetainedEarningsAccumulatedLosses 2025-11-30 SC520422 ns5:RetainedEarningsAccumulatedLosses 2024-11-30 SC520422 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-11-30 SC520422 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-11-30

REGISTERED NUMBER: SC520422

GLOBAL CLINICAL TRIAL PARTNERS LTD

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 NOVEMBER 2025

GLOBAL CLINICAL TRIAL PARTNERS LTD (REGISTERED NUMBER: SC520422)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2025

Page |

Balance Sheet | 1 |

Notes to the Financial Statements | 2 |

GLOBAL CLINICAL TRIAL PARTNERS LTD (REGISTERED NUMBER: SC520422)

BALANCE SHEET

30 NOVEMBER 2025

| 2025 |  | 2024

| Notes | £ | £ |

CURRENT ASSETS

Debtors | 4 | 151,310 |  | 141,991 |  |

Cash at bank | 2,712,303 |  | 2,239,534 |  |

2,863,613 |  | 2,381,525 |  |

CREDITORS

Amounts falling due within one year | 5 | 199,786 |  | 218,341 |  |

NET CURRENT ASSETS | 2,663,827 |  | 2,163,184 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 2,663,827 |  | 2,163,184 |  |

CAPITAL AND RESERVES

Called up share capital | 100 |  | 100 |  |

Retained earnings | 2,663,727 |  | 2,163,084 |  |

SHAREHOLDERS' FUNDS | 2,663,827 |  | 2,163,184 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 August 2026 and were signed on its behalf by:

M R Macdonald - Director

GLOBAL CLINICAL TRIAL PARTNERS LTD (REGISTERED NUMBER: SC520422)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2025

1. | STATUTORY INFORMATION

| Global Clinical Trial Partners Ltd is a private company, limited by shares, registered in Scotland. The company's registered office is 272 Bath Street, Glasgow, Scotland, G2 4JR.

| The presentation currency is Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. There were no material departures from that standard. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover represents invoiced sales of services excluding value added tax. The company's policy is to recognise a sale when substantively all the risks and rewards in connection with the services have been passed to the buyer.

| Judgements

| The company considers on an annual basis the judgements that are made by management when applying its significant accounting policies that would have the most significant effect on amounts that are recognised in the financial statements.

| The directors consider there are no such significant judgements.

| Financial instruments

| The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable and loans to and from related parties.

| Debt instruments like loans and other accounts receivable and payable are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and trade creditors, are measured, initially and subsequently, at the undiscounted amount of cash or other consideration expected to be paid or received.

| Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for evidence of impairment and if found, an impairment loss is recognised in profit or loss.

| Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

| Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within borrowings in current liabilities.

GLOBAL CLINICAL TRIAL PARTNERS LTD (REGISTERED NUMBER: SC520422)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 NOVEMBER 2025

2. | ACCOUNTING POLICIES - continued

| Taxation

| Taxation represents the sum of tax currently payable and deferred tax. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

| The charge for taxation takes into account taxation deferred as a result of timing differences between the treatment of certain items for taxation and accounting purposes. In general, deferred taxation is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. However, deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. Deferred taxation is measured on a non-discounted basis at the tax rates that are expected to apply in the periods in which the timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date.

| With the exception of changes arising on the initial recognition of a business combination, the tax expense is presented either in profit or loss, other comprehensive income or statement of changes in equity depending on the transaction that resulted in the tax expense.

| Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Provisions

| Provisions are recognised when the company has a legal or constructive obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was NIL (2024 - NIL).

4. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 143,257 |  | 134,848 |  |

| Other debtors | 8,053 |  | 7,143 |  |

151,310 |  | 141,991 |  |

5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 26,841 |  | 13,711 |  |

| Taxation and social security | 167,714 |  | 201,586 |  |

| Other creditors | 5,231 |  | 3,044 |  |

199,786 |  | 218,341 |  |